Cochrane · systematic review · CD011293
Sublingual immunotherapy for asthma
Fortescue, R, Kew, KM, Leung, MShiu Tsun · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 2 · 28.6%Low 2 · 28.6%Moderate 1 · 14.3%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySublingual immunotherapy versus control for asthma
Population: adults and children with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks Sublingual immunotherapy vs control | OR 0.35 [0.1, 1.2] | 2 studies · 108 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Quality of life Sublingual immunotherapy vs control | no estimate extracted | NR | No studies |
Serious adverse events Weighted mean duration of studies: 56 weeks Sublingual immunotherapy vs control | no estimate extracted | 29 studies · 4810 participants | Moderate Downgraded: risk of bias, indirectness |
Exacerbation requiring OCS Weighted mean duration of studies: 58 weeks Sublingual immunotherapy vs control | OR 0.75 [0.45, 1.24] | 5 studies · 1364 participants | Very low Downgraded: imprecision, indirectness, publication bias |
All adverse events Weighted mean duration of studies: 62 weeks** Sublingual immunotherapy vs control | OR 1.99 [1.49, 2.67] | 27 studies · 4251 participants | High |
Bronchial provocation Sublingual immunotherapy vs control | no estimate extracted | 5 studies · 200 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
ICS use Sublingual immunotherapy vs control | no estimate extracted | 3 studies · 778 participants | Low Downgraded: imprecision, indirectness |
SLIT vs control
Population: adults and children with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation requiring ED or hospital visit Study duration: 4 weeks SLIT vs control | no estimate extracted | 1 study · 47 participants | Low Downgraded: imprecision |
Quality of life SLIT vs control | no estimate extracted | 0 studies · 0 participants | Ungraded |
Serious adverse events Weighted mean duration of studies: 49 weeks SLIT vs control | RD 0.0012 | 22 studies · 2560 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Exacerbation requiring OCS Weighted mean duration of studies: 25 weeks SLIT vs control | no estimate extracted | 2 studies · 77 participants | Low Downgraded: imprecision |
All adverse events Weighted mean duration of studies: 60 weeks** SLIT vs control | OR 1.7 [1.21, 2.38] | 19 studies · 1755 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Bronchial provocation SLIT vs control | no estimate extracted | 4 studies · 139 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
ICS use SLIT vs control | no estimate extracted | 2 studies · 174 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |